newsfilter
← Latest News
ACCESS Newswire·

9 Meters Biopharma Provides Business Update and Reports Financial Results for the Second Quarter 2021

- Initiated Phase 2 VIBRANT study of vurolenatide for short bowel syndrome (SBS) in Q2; total stool output (TSO) is primary endpoint following FDA guidance - - Expect Phase 2 data from VIBRANT in Q4 2021 - - Acquired humanized anti-GIP (glucose-depende